Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Diabetic Retinopathy Market Size Growth Expects Significant Thrust at a CAGR of 3% During the Study Period, 2018-30 in the 7MM | DelveInsight | ||||||||||||||||||||||||||||||||||||||||||||||||||
By: PR Newswire Association LLC. - 12 May 2021 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||
A robust pipeline of potential new treatments currently in Phases II and III is expected to drive the Diabetic Retinopathy Market ahead. LAS VEGAS, May 12, 2021 /PRNewswire/ -- DelveInsight's Diabetic Retinopathy Market Insights report offers detailed information on current treatment practices, emerging drugs, Diabetic Retinopathy market share of the individual therapies, current and forecasted Diabetic Retinopathy market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). Some of the key takeaways from the Diabetic Retinopathy Market Insights:
Download report to know which drug is going to capture the maximum market share @ Diabetic Retinopathy Market Analysis and Forecast Diabetic Retinopathy: Disease Overview Diabetic Retinopathy is a significant complication of diabetes mellitus, which is a leading cause of visual loss in working-age populations. With an increasing prevalence of diabetes, it appears that the prevalence of Diabetic Retinopathy is also on the rise. Type 2 diabetes, which is becoming more common, leads to over 60% of patients diagnosing with Diabetic Retinopathy within the first 20 years of onset. Furthermore, Age is a noteworthy risk factor for Diabetic Retinopathy prevalence as the chances increase with the age. Diabetic Retinopathy Epidemiology Segmentation Diabetic Retinopathy Market and Epidemiology Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:
The report proffers a holistic view of the present Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market's hidden potential, and plans strategically to handle market risks. For a comprehensive analysis, visit Diabetic Retinopathy Epidemiological Analysis and Changing Trends Diabetic Retinopathy Therapy Market The present scenario in the Diabetic Retinopathy therapeutic landscape appears quite confined, limited to laser treatment, eye injections, and anti-VEGF drugs, which are the preferred first line of therapy. The treatments for DR relies heavily on the presence of macular edema. Available anti-VEGF drugs include aflibercept (Eylea from Regeneron and Bayer), ranibizumab (Lucentis from Genentech and Novartis), and bevacizumab (Avastin from Genentech) that are presently enjoying the monopoly in the Diabetic Retinopathy market. However, there exist several gaps in the Diabetic Retinopathy therapeutic market in the form of an absence of biomarkers, a lack of technologies that are potential enough to predict the disease course in patients, and novel pathways to offer novel treatments. Reach out to us @ Diabetic Retinopathy Marketed Therapies for more information on available treatment regimens Diabetic Retinopathy Market The Diabetic Retinopathy market encompasses several novel pipeline therapies with better efficiency and tolerability than conventional and available therapies. Key companies such as Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Kubota Vision, Allegro Ophthalmics, and several others are developing new drugs that project a promising picture of the Diabetic Retinopathy market landscape in the coming decade. The market has limited options to offer, and a lack of gene therapy, personalized treatment approaches offer pharma companies a latitude to explore and penetrate with novel gene therapies, biosimilars into the market. This does not only promise one-time treatment but also facilitates the usage of lower doses ascribed to favorable anatomy of the eye owing to its size. Moreover, an increasing patient pool also gives pharma companies room for making cost-effective drugs without compromising with gains. Different possible pathways have been extensively studied, which could be responsible for the disease. Therefore, a better understanding has been obtained through years of thorough research and development. The emergence of personalized medications is expected to further drive the growth of the DR market share. Diabetic Retinopathy Pipeline Therapies and Key Companies Brolucizumabt: Novartis Pharmaceuticals Get a detailed analysis of Diabetic Retinopathy Emerging Drug Pipeline and Key Companies Scope of the Report Coverage: 7MM (the US, EU5, and Japan) Drop by to learn more about the future market trends @ Diabetic Retinopathy Market Landscape and Forecast Table of Contents
Take a tour of the report @ Diabetic Retinopathy Market Forecast and Trends Skim Through Related Reports and Posts DelveInsight's "Diabetic Foot - Market Insights, Epidemiology, and Market Forecast-2030" report. DelveInsight's 'Diabetic Foot Ulcer (DFU) - Market Insights, Epidemiology, and Market Forecast—2030' report offers detailed analysis into epidemiology, treatment landscape and market covering key pharma companies including TissueTech, Aurealis Therapeutics, Rheacell, Oneness Biotech, Biotherapy Services, HelixMith, Lakewood-Amedex, Mallinckrodt, and many others. Diabetic Gastroparesis Market Size DelveInsight's 'Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast-2030 report offers detailed analysis into disease overview (what is diabetic gastroparesis), epidemiology, treatment landscape and market covering key pharma companies including Allergan Evoke Pharma Inc., Theravance Biopharma, Censa Pharmaceuticals, CinDome Pharma, Takeda (Millennium Pharmaceuticals, Inc.), Bird Rock Bio, and others. Diabetic Ketoacidosis Market Diabetic Kidney Disease Market Diabetic Macular Edema Market Diabetic Peripheral Neuropathy Market Landscape Related Posts Understanding The Increasing Prevalence Of Diabetes And Its Complications Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare and Biotech News Contact Us Shruti Thakur Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2021 PR Newswire Association LLC. | Back to overview list |